Hepatoma-derived growth factor

HDGF

Available structures

Ortholog search: PDBe RCSB

List of PDB id codes
1RI0, 2NLU

Identifiers

Aliases

HDGF, HMG1L2, hepatoma-derived growth factor

External IDs

MGI: 1194494 HomoloGene: 3306 GeneCards: HDGF

Gene ontology
Molecular function	• nucleotide binding • DNA binding • transcription corepressor binding • poly(A) RNA binding • RNA polymerase II transcription corepressor activity • growth factor activity • heparin binding
Cellular component	• cytoplasm • extracellular space • transcriptional repressor complex • nucleus • nucleoplasm
Biological process	• IRE1-mediated unfolded protein response • cell proliferation • regulation of transcription, DNA-templated • negative regulation of transcription from RNA polymerase II promoter • transcription, DNA-templated • signal transduction
Sources:Amigo / QuickGO

RNA expression pattern

More reference expression data

Orthologs

Species

Human

Mouse

Entrez


3068


15191

Ensembl


ENSG00000143321


ENSMUSG00000004897

UniProt


P51858


P51859

RefSeq (mRNA)

NM_001126050 NM_001126051 NM_004494 NM_001319186 NM_001319187
NM_001319188


NM_008231

RefSeq (protein)

NP_001119522.1 NP_001119523.1 NP_004485.1 NP_001306115.1 NP_001306116.1
NP_001306117.1


NP_032257.3

Location (UCSC)

Chr 1: 156.74 – 156.77 Mb

Chr 3: 87.91 – 87.92 Mb

PubMed search

^[1]

^[2]

Wikidata

View/Edit Human

View/Edit Mouse

Hepatoma-derived growth factor (HDGF) also known as high mobility group protein 1-like 2 (HMG-1L2) is a protein that in humans is encoded by the HDGF gene.^[3]^[4]

References

↑ "Human PubMed Reference:".
↑ "Mouse PubMed Reference:".
↑ Wanschura S, Schoenmakers EF, Huysmans C, Bartnitzke S, Van de Ven WJ, Bullerdiek J (May 1997). "Mapping of the gene encoding the human hepatoma-derived growth factor (HDGF) with homology to the high-mobility group (HMG)-1 protein to Xq25". Genomics. 32 (2): 298–300. doi:10.1006/geno.1996.0122. PMID 8833162.
↑ "Entrez Gene: HDGF hepatoma-derived growth factor (high-mobility group protein 1-like)".

Everett AD, Bushweller J (2003). "Hepatoma derived growth factor is a nuclear targeted mitogen.". Current drug targets. 4 (5): 367–71. doi:10.2174/1389450033490975. PMID 12816346.
Nakamura H, Izumoto Y, Kambe H, et al. (1994). "Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein.". J. Biol. Chem. 269 (40): 25143–9. PMID 7929202.
Kishima Y, Yamamoto H, Izumoto Y, et al. (2002). "Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals.". J. Biol. Chem. 277 (12): 10315–22. doi:10.1074/jbc.M111122200. PMID 11751870.
Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
Mori M, Morishita H, Nakamura H, et al. (2004). "Hepatoma-derived growth factor is involved in lung remodeling by stimulating epithelial growth.". Am. J. Respir. Cell Mol. Biol. 30 (4): 459–69. doi:10.1165/rcmb.2003-0013OC. PMID 12972397.
Yoshida K, Nakamura H, Okuda Y, et al. (2004). "Expression of hepatoma-derived growth factor in hepatocarcinogenesis.". J. Gastroenterol. Hepatol. 18 (11): 1293–301. doi:10.1046/j.1440-1746.2003.03191.x. PMID 14535987.
Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
Shu H, Chen S, Bi Q, et al. (2004). "Identification of phosphoproteins and their phosphorylation sites in the WEHI-231 B lymphoma cell line.". Mol. Cell Proteomics. 3 (3): 279–86. doi:10.1074/mcp.D300003-MCP200. PMID 14729942.
Everett AD, Narron JV, Stoops T, et al. (2004). "Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor.". Am. J. Physiol. Lung Cell Mol. Physiol. 286 (6): L1194–201. doi:10.1152/ajplung.00427.2003. PMID 14751852.
Sue SC, Chen JY, Huang TH (2004). "Sequence specific 1H, 13C and 15N resonance assignments of the hath-domain of human hepatoma-derived growth factor.". J. Biomol. NMR. 29 (1): 95–6. doi:10.1023/B:JNMR.0000019467.57276.05. PMID 15017145.
Beausoleil SA, Jedrychowski M, Schwartz D, et al. (2004). "Large-scale characterization of HeLa cell nuclear phosphoproteins.". Proc. Natl. Acad. Sci. U.S.A. 101 (33): 12130–5. doi:10.1073/pnas.0404720101. PMC 514446. PMID 15302935.
Ballif BA, Villén J, Beausoleil SA, et al. (2005). "Phosphoproteomic analysis of the developing mouse brain.". Mol. Cell Proteomics. 3 (11): 1093–101. doi:10.1074/mcp.M400085-MCP200. PMID 15345747.
Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
Shen XY, Zacal N, Singh G, Rainbow AJ (2005). "Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells.". Photochem. Photobiol. 81 (2): 306–13. doi:10.1562/2004-07-22-RA-242. PMID 15560738.
Barrios-Rodiles M, Brown KR, Ozdamar B, et al. (2005). "High-throughput mapping of a dynamic signaling network in mammalian cells.". Science. 307 (5715): 1621–5. doi:10.1126/science.1105776. PMID 15761153.
Iwasaki T, Nakagawa K, Nakamura H, et al. (2005). "Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.". Oncol. Rep. 13 (6): 1075–80. doi:10.3892/or.13.6.1075. PMID 15870924.
Gregory SG, Barlow KF, McLay KE, et al. (2006). "The DNA sequence and biological annotation of human chromosome 1.". Nature. 441 (7091): 315–21. doi:10.1038/nature04727. PMID 16710414.
Beranova-Giorgianni S, Zhao Y, Desiderio DM, Giorgianni F (2006). "Phosphoproteomic analysis of the human pituitary.". Pituitary. 9 (2): 109–20. doi:10.1007/s11102-006-8916-x. PMID 16807684.
Clermont F, Gonzalez NS, Communi D, Franken S, Dumont JE, Robaye B (2008). "HDGF is dephosphorylated during the early steps of endothelial cell apoptosis in a caspase-dependent way.". J Cell Biochem. 104 (4): 1161–1171. doi:10.1002/jcb.21788. PMID 18465786.

PDB gallery

1ri0: NMR structure of the N-terminal hath domain of human HDGF

2b8a: High Resolution Structure of the HDGF PWWP Domain

Growth factor receptor modulators

Angiopoietin

Agonists: Angiopoietin 1
Angiopoietin 4

Antagonists: Angiopoietin 2
Angiopoietin 3

Antibodies: Evinacumab (against angiopoietin 3)
Nesvacumab (against angiopoietin 2)

CNTF

Agonists: Axokine
CNTF
Dapiclermin

EGF (ErbB)

EGF (ErbB1/HER1)	Agonists: Amphiregulin Betacellulin EGF (urogastrone) Epigen Epiregulin Heparin-binding EGF-like growth factor (HB-EGF) Murodermin Nepidermin Transforming growth factor alpha (TGFα) Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab Kinase inhibitors: Afatinib AG-490 Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154

ErbB2/HER2	Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab duocarmazine Trastuzumab emtansine Kinase inhibitors: Afatinib AG-490 Lapatinib Mubritinib Neratinib

ErbB3/HER3	Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies: Duligotumab Patritumab Seribantumab

ErbB4/HER4	Agonists: Betacellulin Epigen Heparin-binding EGF-like growth factor (HB-EGF) Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))

FGF

FGFR1	Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20) Repifermin Trafermin Velafermin

FGFR2	Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22) Palifermin Repifermin Sprifermin Trafermin Antibodies: Aprutumab Aprutumab ixadotin

FGFR3	Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Sprifermin Trafermin Antibodies: Burosumab (against FGF23)

FGFR4	Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8, 9, 19) Trafermin

Unsorted	Agonists: FGF15/19

HGF (c-Met)

Agonists: Hepatocyte growth factor

Potentiators: Dihexa (PNB-0408)

Antibodies: Emibetuzumab
Ficlatuzumab
Flanvotumab
Onartuzumab
Rilotumumab
Telisotuzumab
Telisotuzumab vedotin

Kinase inhibitors: AM7 (drug)
AMG-458
Amuvatinib
BMS-777607
Cabozantinib
Crizotinib
Foretinib
Golvatinib
INCB28060
JNJ-38877605
K252a
MK-2461
PF-04217903
PF-2341066
PHA-665752
SU-11274
Tivantinib
Volitinib

IGF

IGF-1	Agonists: des(1-3)IGF-1 Insulin-like growth factor-1 (somatomedin C) IGF-1 LR3 Insulin-like growth factor-2 (somatomedin A) Insulin Mecasermin Mecasermin rinfabate Antagonists: BMS-754807 Antibodies: AVE1642 Cixutumumab Dalotuzumab Figitumumab Ganitumab Robatumumab R1507 Teprotumumab Kinase inhibitors: Linsitinib NVP-ADW742 NVP-AEW541 OSl-906

IGF-2	Agonists: Insulin-like growth factor-2 (somatomedin A) Antibodies: Dusigitumab

Others	Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7) Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) Trofinetide

LNGF

Agonists: BDNF
Cenegermin
NGF
NT-3
NT-4

Antagonists: SAR127963

Antibodies: Against NGF: Fasinumab
Fulranumab
Ranevetmab
Tanezumab

PDGF

Agonists: Becaplermin
Platelet-derived growth factor (A, B, C, D)

RET (GFL)

GFRα1	Agonists: Glial cell line-derived neurotrophic factor (GDNF) Liatermin Kinase inhibitors: Vandetanib

GFRα2	Agonists: Neurturin (NRTN) Kinase inhibitors: Vandetanib

GFRα3	Agonists: Artemin (ARTN) Kinase inhibitors: Vandetanib

GFRα4	Agonists: Persephin (PSPN) Kinase inhibitors: Vandetanib

Unsorted	Kinase inhibitors: Agerafenib

SCF (c-Kit)

Agonists: Ancestim
Stem cell factor

TGFβ

See here instead.

Trk

TrkA	Agonists: Amitriptyline Cenegermin Gambogic amide NGF Tavilermide Antagonists: FX007 Kinase inhibitors: Entrectinib K252a Lestaurtinib LOXO-101 Antibodies: Against NGF: Fasinumab Fulranumab Ranevetmab Tanezumab

TrkB	Agonists: 3,7-DHF 3,7,8,2'-THF 4'-DMA-7,8-DHF 7,3'-DHF 7,8-DHF 7,8,2'-THF 7,8,3'-THF Amitriptyline BDNF Deoxygedunin Diosmetin HIOC LM22A-4 N-Acetylserotonin NT-3 NT-4 Norwogonin (5,7,8-THF) R7 TDP6 Antagonists: ANA-12 Cyclotraxin B Gossypetin (3,5,7,8,3',4'-HHF) Kinase inhibitors: Entrectinib K252a Lestaurtinib LOXO-101

TrkC	Agonists: NT-3 Kinase inhibitors: Entrectinib K252a Lestaurtinib LOXO-101

VEGF

Agonists: Placental growth factor (PGF)
Telbermin
VEGF (A, B, C, D (FIGF))

Allosteric modulators: Cyclotraxin B

Decoy receptors: Aflibercept

Others

Additional growth factors: Adrenomedullin
Colony-stimulating factors (see here instead)
Connective tissue growth factor (CTGF)
Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
Erythropoietin (see here instead)
Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
Glia maturation factor (GMF)
Hepatoma-derived growth factor (HDGF)
Interleukins/T-cell growth factors (see here instead)
Leukemia inhibitory factor (LIF)
Macrophage-stimulating protein (MSP; HLP, HGFLP)
Midkine (NEGF2)
Migration-stimulating factor (MSF; PRG4)
Oncomodulin
Pituitary adenylate cyclase-activating peptide (PACAP)
Pleiotrophin
Renalase
Thrombopoietin (see here instead)
Wnt signaling proteins

Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)

See also: Peptide receptor modulators
Cytokine receptor modulators

This article is issued from Wikipedia - version of the 5/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

Hepatoma-derived growth factor

References

Further reading